MedTrace Logo

Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer

NCT04608409 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2025-06-29

Study results available
· View outcomes & findings →

Summary

This trial will be a phase I dose-escalation study of lapatinib and paclitaxel for platinum-resistant ovarian cancer, which will establish the phase II dose for subsequent efficacy trials.

Conditions

Interventions

DRUG

Lapatinib and Paclitaxel

Participants will receive twice-daily Lapatinib, beginning two days prior to Paclitaxel treatment.

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Frederick R. Ueland, M.D.

    lead OTHER

Principal Investigators

  • Frederick Ueland, MD · Markey Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-17
Primary Completion
2024-05-17
Completion
2024-05-17
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04608409 on ClinicalTrials.gov